Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael W N Deininger

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Cancer Cell|November 3, 2009
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceThomas O'Hare, William C Shakespeare, Xiaotian Zhu, et al.
The New England Journal of Medicine|December 8, 2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaBrian J Druker, François Guilhot, Stephen G O'Brien, et al.
The New England Journal of Medicine|December 12, 2019
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P Hughes, Michael J Mauro, Jorge E Cortes, et al.
Blood|May 3, 2002
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyCharles L Sawyers, Andreas Hochhaus, Eric Feldman, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Cancer Cell|November 3, 2009
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistanceThomas O'Hare, William C Shakespeare, Xiaotian Zhu, et al.
The New England Journal of Medicine|December 8, 2006
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaBrian J Druker, François Guilhot, Stephen G O'Brien, et al.
The New England Journal of Medicine|December 12, 2019
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor FailureTimothy P Hughes, Michael J Mauro, Jorge E Cortes, et al.
Blood|May 3, 2002
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyCharles L Sawyers, Andreas Hochhaus, Eric Feldman, et al.
Pageof 6